Correlation between circulating adiponectin levels and coronary plaque regression during aggressive lipid-lowering therapy in patients with acute coronary syndrome: Subgroup analysis of JAPAN-ACS study

Taiki Ohashi, Rei Shibata, Takeshi Morimoto, Masaaki Kanashiro, Hideki Ishii, Satoshi Ichimiya, Takafumi Hiro, Katsumi Miyauchi, Yoshihisa Nakagawa, Masakazu Yamagishi, Yukio Ozaki, Takeshi Kimura, Hiroyuki Daida, Toyoaki Murohara, Masunori Matsuzaki

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

Objective: The Japan assessment of pitavastatin and atorvastatin in acute coronary syndrome (JAPAN-ACS) study demonstrated that aggressive lipid-lowering therapy with a statin resulted in a significant regression of coronary atherosclerotic plaques in patients with ACS. Adiponectin is an adipocyte-derived protein with anti-atherogenic properties. Here, we investigated the association between adiponectin levels and the change in the plaque volume in ACS patients. Methods: Intravascular ultrasound (IVUS)-guided percutaneous coronary intervention (PCI) was undertaken, followed by the initiation of statin treatment, in 238 patients with ACS. Follow-up IVUS was performed between 8 and 12 months after the PCI. The percent change in the plaque volume (%PV) in a non-culprit coronary artery segment was evaluated. The serum adiponectin and lipid parameters were measured both at baseline and at the follow-up. Results: At baseline, adiponectin was correlated positively with HDL-cholesterol and negatively correlated with triglyceride, but no correlation was observed with the PV. Adiponectin levels increased significantly from 7.8 ± 4.6 μg/mL at baseline to 10.3 ± 6.9 μg/mL at the 8-12 months follow-up. The increase in adiponectin was also associated with an increase of HDL-cholesterol and decrease of triglyceride, however, no significant correlation was observed with the %PV. A significantly higher incidence of major adverse cardiac events (MACE) was observed in patients with hypo-adiponectinemia at baseline. A multiple logistic regression analysis identified adiponectin as a significant independent predictor of MACE. Conclusion: Adiponectin levels measured after PCI could serve as a marker of MACE in patients with ACS.

Original languageEnglish
Pages (from-to)237-242
Number of pages6
JournalAtherosclerosis
Volume212
Issue number1
DOIs
Publication statusPublished - 09-2010

All Science Journal Classification (ASJC) codes

  • Cardiology and Cardiovascular Medicine

Fingerprint Dive into the research topics of 'Correlation between circulating adiponectin levels and coronary plaque regression during aggressive lipid-lowering therapy in patients with acute coronary syndrome: Subgroup analysis of JAPAN-ACS study'. Together they form a unique fingerprint.

  • Cite this

    Ohashi, T., Shibata, R., Morimoto, T., Kanashiro, M., Ishii, H., Ichimiya, S., Hiro, T., Miyauchi, K., Nakagawa, Y., Yamagishi, M., Ozaki, Y., Kimura, T., Daida, H., Murohara, T., & Matsuzaki, M. (2010). Correlation between circulating adiponectin levels and coronary plaque regression during aggressive lipid-lowering therapy in patients with acute coronary syndrome: Subgroup analysis of JAPAN-ACS study. Atherosclerosis, 212(1), 237-242. https://doi.org/10.1016/j.atherosclerosis.2010.05.005